Quantum convoy covers 1,000 miles for cancer

Pharmaceutical specials manufacturer raises £5,000 for charity

Ten amateur cyclists from pharmaceutical manufacturer Quantum Pharmaceutical have completed a 1,000-mile charity bike ride to raise £5,000 for Marie Curie Cancer Care.

The team signed up for the challenge after their colleague Tony Gallagher died of cancer in 2008.

Gallagher’s son, Scott, led the cycle convoy, which rode off from Land’s End in Cornwall and cycled up to 90 miles a day to cross the finishing line at John O’Groats in Caithness, Scotland a fortnight later.

‘It was a testing couple of weeks,’ said Quantum Pharmaceutical’s managing director Andy Scaife.

‘We remember Tony so fondly, and cycling a thousand miles will be nothing compared with the challenge he faced in fighting cancer. We just hope the money we raise will help other cancer sufferers as they battle with the disease.’

Quantum Pharmaceutical, based in Burnopfield, Co Durham, UK, is a pharmaceutical specials manufacturer licensed by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to supply pharmacies, chemists, dispensing doctors and hospitals with bespoke medicines.

You may also like

Regulatory

Penn Pharma recalls batches of seizure drug

Following incorrect placement of screw caps on some units of Midazolam buccal liquid, which could affect drug concentration
Containment

Quantum Pharmaceutical opens aseptic manufacturing facility

Incorporates aseptic compounding and manufacturing services, including gassing isolators
Manufacturing

Quantum Pharmaceutical moves into new HQ

Opens up potential for further expansion of the UK specials manufacturer
Regulatory

Standard proposed to clarify endotoxin testing for single-use systems

The guide will address variability when assessing bacterial endotoxins on large-scale pharmaceutical equipment
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Personal Protection

Almost 60% of workplace injuries from harmful substances are burns

Chemical burns continue to be the leading type of non-fatal injury caused by exposure to or contact with harmful substances in workplaces across Great Britain
Subscribe now